Hormonal
Retatrutide significantly improves glycemic control, including reductions in HbA1c, fasting glucose, and daily mean blood glucose, in patients with obesity and/or type 2 diabetes.
For those with type 2 diabetes or obesity, retatrutide helps lower blood sugar levels (HbA1c, fasting glucose) effectively. This is achieved through weekly injections that mimic natural hormones to regulate glucose. The benefit is particularly pronounced for those who already have diabetes.
Also, there was a significant reduction in HbA1c (WMD –0.90 %; 95 % CI –1.63, – 0.17; p = 0.02; I2 = 89 %; Fig. 4A), daily mean blood glucose (WMD –2.07 mmol/L; 95 % CI –2.75, – 1.40; p < 0.01; I2 = 0 %; Fig. 4B), and fasting glucose (WMD –1.24 mmol/L; 95 % CI –2.24, – 0.23; p = 0.02; I2 = 75 %; Fig. 4C) in favor of the retatrutide group, compared with placebo.
Why this rating
Based on 3 RCTs with moderate to high heterogeneity (I2 up to 89% for HbA1c) and GRADE assessment of 'low-quality' evidence for HbA1c.
Source
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials
Eric Pasqualotto et al. · Metabolism Open · 2024
DOI 10.1016/j.metop.2024.100321
More from this paper
- Retatrutide increases the rate of gastrointestinal adverse events (nausea, vomiting, constipation) and hypersensitivity reactions compared to placebo, but does not significantly increase serious adverse events.Good
- Once-weekly subcutaneous retatrutide significantly reduces body weight, BMI, and waist circumference in patients with overweight, obesity, and/or type 2 diabetes compared to placebo.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →